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Characterization of pathogenic SORL1 genetic variants
for association with Alzheimer’s disease: a clinical
interpretation strategy
Henne Holstege*,1,2,3, Sven J van der Lee1,4, Marc Hulsman2,3, Tsz Hang Wong5, Jeroen GJ van Rooij5,6,
Marjan Weiss2, Eva Louwersheimer1, Frank J Wolters4, Najaf Amin4, André G Uitterlinden4,6,7,
Albert Hofman4,8, M Arfan Ikram4,5,9, John C van Swieten1,5, Hanne Meijers-Heijboer2,
Wiesje M van der Flier1,10, Marcel JT Reinders3, Cornelia M van Duijn4,11 and Philip Scheltens1
Accumulating evidence suggests that genetic variants in the SORL1 gene are associated with Alzheimer disease (AD), but a
strategy to identify which variants are pathogenic is lacking. In a discovery sample of 115 SORL1 variants detected in 1908
Dutch AD cases and controls, we identiﬁed the variant characteristics associated with SORL1 variant pathogenicity. Findings
were replicated in an independent sample of 103 SORL1 variants detected in 3193 AD cases and controls. In a combined
sample of the discovery and replication samples, comprising 181 unique SORL1 variants, we developed a strategy to classify
SORL1 variants into ﬁve subtypes ranging from pathogenic to benign. We tested this pathogenicity screen in SORL1 variants
reported in two independent published studies. SORL1 variant pathogenicity is deﬁned by the Combined Annotation Dependent
Depletion (CADD) score and the minor allele frequency (MAF) reported by the Exome Aggregation Consortium (ExAC) database.
Variants predicted strongly damaging (CADD score 430), which are extremely rare (ExAC-MAF o1×10−5) increased AD risk
by 12-fold (95% CI 4.2–34.3; P=5×10−9). Protein-truncating SORL1 mutations were all unknown to ExAC and occurred
exclusively in AD cases. More common SORL1 variants (ExAC-MAF≥1×10−5) were not associated with increased AD risk, even
when predicted strongly damaging. Findings were independent of gender and the APOE-ε4 allele. High-risk SORL1 variants were
observed in a substantial proportion of the AD cases analyzed (2%). Based on their effect size, we propose to consider high-risk
SORL1 variants next to variants in APOE, PSEN1, PSEN2 and APP for personalized risk assessments in clinical practice.
European Journal of Human Genetics (2017) 25, 973–981; doi:10.1038/ejhg.2017.87; published online 24 May 2017
INTRODUCTION
Approximately one-third of the population older than 85 years has
Alzheimer’s disease (AD).1 Despite intensive research, the pathophy-
siology underlying AD is still poorly understood. The risk to develop
(non-Mendelian) AD is estimated to be 60–80% heritable,2 suggesting
that the identiﬁcation of genetic determinants of AD will provide
further insights into underlying molecular mechanisms of AD.
Rapidly accumulating genetic and biological evidence suggests that
disturbed function of the sortilin-related receptor 1 (SORL1) is
associated with AD.3–7 Functional SORL1 reduces the amyloid-β levels
in the brain, thereby reducing the load of neurotoxic amyloid-β
plaques, a neuropathological hallmark of AD.8 SORL1 reduces
amyloid-β levels (i) by binding the amyloid precursor protein
(APP), preventing its processing into amyloid-β and (ii) by binding
amyloid-β and directing it to the lysosome for degradation.
To exert its function, the SORL1 protein includes domains from the
low-density lipoprotein receptor-like family, including complement-
type repeats that interact in a 1:1 stoichiometric complex with APP.9,10
The SORL1 protein also includes a VPS10 domain from the vacuolar
protein sorting-10 receptor family, which binds soluble Aβ for
endosomal inclusion and sorting for lysosomal degradation.11,12
Therefore, impaired SORL1 function is associated both with disturbed
APP processing and disturbed Aβ degradation, two central events
underlying the pathophysiology of AD.13–16
Since 2007, a multitude of studies associated both common and rare
variants in the SORL1 gene with AD,17–21 but different variants were
associated across studies and risk-effects ranged from small modifying
effects to causal effects.22,23 In genome-wide association studies
(GWAS) including thousands of AD cases and controls, common
genetic variants near and in the SORL1 gene were found to associate
signiﬁcantly with AD.24 However, each of these variants confer only a
small increase in AD risk (OR=~1.2), which is comparable to the
small changes in AD risk conferred by the other ~ 20 genetic loci
that were also identiﬁed in these GWAS studies (reviewed by
Van Cauwenberghe et al.25). In contrast, recent studies reported that
rare SORL1 variants are associated with a ﬁve-fold increased risk for
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early onset AD.5,6 These studies suggest that the effect on AD risk of
these rare SORL1 variants is comparable to that of carrying the ε4
allele of Apolipoprotein-E gene (APOE), the most important common
risk factor for AD; homozygous and heterozygous APOE-ε4 carriers
are respectively exposed to a 3 to 5-fold increased AD risk and 10 to
15-fold increased AD risk compared with non-APOE-ε4 carriers.26
Furthermore, recent targeted sequencing studies identiﬁed rare
pathogenic SORL1 mutations that segregated with disease in families
with familial AD and late onset AD.3,4 These ﬁndings suggest that
speciﬁc SORL1 variants are causal for AD, with effects comparable to
single mutations in the APP gene,27 or the presenilin-1 and presenilin-
2 genes (PSEN1, PSEN2),28,29 that are associated with an autosomal
dominant inheritance pattern of AD. However, it is currently unclear
which speciﬁc SORL1 variants are major risk factors for AD and which
can be considered benign. This raises the need for a strategy to
determine SORL1 variant pathogenicity.
Ideally, one would like to determine penetrance for each detected
SORL1 variant in multiple large and informative families. However,
the rareness of the SORL1 variants that were thus far associated with
AD complicates such efforts.3–6 Therefore, a more feasible approach
might be to distinguish between pathogenic and non-pathogenic
variants using independent variant characteristics that might be
associated with SORL1 variant pathogenicity. In this work we explored
the contribution on disease outcome of (i) the functional protein
domain affected by the SORL1 variant; (ii) the minor allele frequency
(MAF) of the SORL1 variant in the population; and (iii) predicted
damagingness of the SORL1 variant on the basis of sequence context.
To predict the damagingness of SORL1 variants we annotated them
with the CADD score,30 a novel functional annotation tool that allows
for an unbiased annotation of almost all variants in the human
genome. The CADD score reﬂects the difference between the
characteristics of genetic variation that is tolerated (ﬁxed) in the
human genome and the characteristics of pathogenic variants (ran-
domly simulated variants enriched with pathogenic variants). Scores
are based on 460 functional prediction tools that include functional
annotations, allelic conservation and regulatory effects.
The MAF of a variant can be derived from the (large) sample in
which it was discovered, but also from publically available databases
such as the ExAC database,31 which includes variants detected in a set
of 60 706 exomes. Importantly, the MAF per variant is not included in
determining its CADD score, such that the CADD score and MAF can
be used as independent determinants of variant pathogenicity.
We determined the characteristics of SORL1 variant pathogenicity
in a discovery sample consisting of 640 Dutch early- and late onset AD
patients and in 1268 older Dutch cognitively healthy controls. We
tested whether these characteristics replicated in an independent data
set reported by Verheijen et al.6 and we performed a combined
analysis including data from both studies. Based on these results, we
suggest ﬁve SORL1 variant subtypes according to the ﬁve-class system
of variant pathogenicity supported by the American College of Medical
Genetics and Genomics (ACMG)32 and Association for Clinical
Genetic Science (ACGS).33 Lastly, we validated our classiﬁcation
strategy by applying it to SORL1 variants described in two additional
independent publications.4,5
MATERIAL AND METHODS
Detailed methods are described in the Supplementary Methods.
Samples
For a schematic overview of the analysis setup see Figure 1.
Discovery sample. The exome collection was assembled from four Dutch
studies: (i) the Rotterdam Study34 contributed 250 AD cases (median age at
disease onset 84.5± 6.62, 71.2% females) and 1204 controls (median age at last
visit of 82.4± 6.8, 54.3% females), (ii) The Amsterdam Dementia Cohort
(ADC-VUmc) contributed 320 AD (median age of 58.4± 6.5, 51.9%
females),35 (iii) the Alzheimer Centrum Zuidwest Nederland (ACZN) cohort
contributed 80 AD cases (median age 59.2± 7.2, 57.1% females) and (iv) the
100-plus Study (www.100plus.nl) contributed 64 controls (median age of 101.1
years± 3.5, 79.7% females).
In total, 1908 exomes passed quality control: 640 cases (median age at onset
of 64.8 years, IQR: 57.3–82.2, 60% females) and 1268 controls (median age at
last screening of 82.7 years, IQR 78.3–87.6, 55.6% females) (for cohort
characteristics see Supplementary Table S1; for age distribution of cases and
controls see Supplementary Figure S1). No known AD-causing mutations were
detected in the APP, PSEN1 and PSEN2 genes. Combined data included (i) AD
status, (ii) APOE status, (iii) gender and (iv) age at onset for AD and (v) age at
last screening for controls.
Replication sample. We performed a replication analysis in an independent
data set recently published by Verheijen et al.6 They reported 103 SORL1
variants in 1255 European early onset AD cases and 1938 age-matched controls.
Rare SORL1 variants that occurred in either cases or controls were given per
subject (including gender and age, but not APOE genotype), and no two
variants occurred in the same subject; the number of case- and control-carriers
were given for rare SORL1 variants that occurred in both cases and controls;
common SORL1 variants (MAF40.01 in the sample) were available as sample-
MAFs. For an in-depth analysis of independence between the discovery and the
replication samples, see Supplementary Data and Supplementary Table S2.
Exome sequencing and variant detection in discovery sample
Exomes from the Rotterdam Study and the ACZN cohort were captured with
the Nimblegen v2 Seqcap EZ Exome capture kit. The exomes from the ADC-
VUmc cohort and the 100-plus Study cohort were captured with the
Nimblegen SeqCap EZ Exome capture kit v3. For SORL1 variant calling, we
used the intersection between these capture kits in the SORL1 gene: 93.2% of
Figure 1 Flowchart of SORL1 variant pathogenicity analysis. aSORL1
variants in the independent replication data set were reported by Verheijen
et al.6 Pathogenicity screen was applied to SORL1 variants reported by
bVardarajan et al.4 and cNicolas et al.5
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exons 1–47, 2.7% of exon 48. DNA from all samples was prepared with the
Illumina TruSeq Paired-End Library Preparation Kit and 100 bp paired-end
reads were acquired by sequencing the libraries on a HiSeq 2000 or 2500. We
sequenced to at least 40× mean coverage to ensure sufﬁcient read depth for
variant calling.
We removed population outliers based on the ﬁrst two PCA components
and those with an identity by decent value40.1. Technical differences between
data acquisition commonly introduces ‘differential missingness’ (ie, loci may be
genotyped in one exome but not in another), which may ultimately result in
unwanted bias towards either cases or controls. To overcome this bias we
implemented additional quality control (see Supplementary Methods) to obtain
a set consisting of 115 true positive variant calls with negligible missingness
across the sample. Variants are listed in Supplementary Table S3, and they are
submitted to the LOVD database (https://databases.lovd.nl/shared/references/
DOI:10.1038/ejhg.2017.87). The subset of variants that were detected only once
in the sample (singleton variants) were validated by Sanger sequencing
(Supplementary Table S4).
Statistical analysis
Variant annotation. Variants were annotated with the CADD score version
1.330 and using the Variant Effect Predictor (VEP) tool in the Ensembl
database.36 Variants were annotated with SIFT v.5.2.2/PolyPhen v.2.2.2 predic-
tion scores (Supplementary Table S3).
Discovery analysis. Since the rarity of most detected variants does not allow a
per-variant calculation of disease association, we tested the burden of all SORL1
variants that adhered to a speciﬁed set of characteristics in AD cases and
controls.37 For this, variant characteristics were based on combinations of the
MAF and CADD scores. The MAF categories included MAF40.01,
0.001oMAFo0.01, 0.0005oMAFo0.001 and MAFo0.0005 (singletons).
The CADD score categories included CADD 0–20 (predicted not or mildly
damaging), 20–30 (predicted moderately damaging) and 430 (predicted
strongly damaging). In addition, variants were stratiﬁed according to SORL1
protein domains. We then performed burden tests using an additive genetic
model and logistic regression score test with the burdenMeta function in the
‘seqMeta’ package v.1.6.038 in R (v3.2.2), while including gender as a covariate.
APOE genotypes were missing for 36 controls and 6 cases; therefore, we
performed separate burden tests using both gender and APOE-ε4 genotype as
covariates. Furthermore, we tested for an interaction effect between the burden
of SORL1 variants and the presence of the APOE-ε4 allele.
Replication analyses were performed with a one-tailed Fisher’s exact test due
to data availability. As rare variants did not overlap between subjects, this
approach is the same as a burden test. Correction for APOE and gender was not
possible because APOE genotypes were not publically available in the
replication sample, and gender only for a sample-subset.
Finally, for a combined analysis of the discovery sample and the replication
sample, we annotated all variants with their MAFs reported in the publically
available ExAC database v.0.3.131 (Supplementary Table S5). To more closely
distinguish between benign and (possibly) pathogenic variants, we stratiﬁed the
CADD tranches into CADD 0–10, 10–20, 20–30 and430. Combined analyses
were performed with a one-tailed Fisher’s exact test.
Multiple testing correction was applied to correct for 70 tests performed in
discovery, replication and combined analysis. P-values lower than 0.05 after
Bonferroni were considered statistically signiﬁcant (Po7.1× 10− 4). We present
unadjusted P-values.
RESULTS
We detected 115 SORL1 variants in the exomes of 640 AD cases and
1268 controls: 4 frameshift, 1 stop-gain, 54 missense, 29 synonymous,
4 regulatory, 4 splice site and 19 intronic variants. Details of the
ﬁltering steps and Sanger validation are in the Supplementary Results.
Of these 115 variants, 15 were common (MAF40.01) and none was
signiﬁcantly associated with AD (Supplementary Table S3). The
remaining 100 variants were rare with an MAFo0.01. These variants
did not occur more often in cases than in controls (OR= 1.2; 95% CI
0.9–1.6; P= 0.23) (Table 1A). There were 36 variants predicted to be
deleterious by SIFT and Polyphen, and these variants were associated
with a two-fold increased AD risk (OR= 1.9; 95% CI 1.2–2.9;
P= 7.2× 10− 3) (Table 1A).
Singleton variants with high CADD score are associated with AD
Of the 100 rare variants (MAFo0.01), 26 variants were predicted
moderately damaging (CADD 20–30) and carrying such a variant is
not associated with a signiﬁcantly increased AD risk (OR= 1.3; 95%
CI 0.78–2.1; P= 0.34) (Table 1A). In contrast, the 19 variants that
were predicted strongly damaging (CADD430) were seen in 15 cases
and 8 controls, such that carrying a variant with these characteristics is
associated with a four-fold increased risk for AD: OR= 4.0; 95% CI
1.7–9.0; P= 9.9 × 10− 4 (Table 1A).
Interestingly, 16 of these 19 predicted strongly damaging variants
with MAFo0.01 were seen only once in our sample: singletons.
Among the 16 carriers of strongly damaging singletons (CADD430),
14 had developed AD, such that strongly damaging singletons were
associated with a 410-fold increase of AD risk (OR= 11.3; 95% CI
4.0–32.1; P= 4.9 × 10− 6). Notably, all ﬁve truncating mutations (stop-
gain/frameshift) were singletons in our sample, and their carriers all
developed AD (P= 1.6 × 10− 3). In sharp contrast, variants with CADD
430 that occur more than once in this sample were not associated
with AD (Table 1B). Gender and carrying the APOE-ε4 genotype did
not inﬂuence these ﬁndings (Supplementary Table S6) and we
detected no evidence for an interaction of a predicted damaging
SORL1 variant (CADD 20–30 or CADD430) and carrying the APOE-
ε4 genotype (Supplementary Table S7 and Supplementary Results). Of
note, no subject carried more than one singleton variant, with the
exception of one control subject who carried two intronic singleton
variants.
The association with AD of singleton variants that were predicted
damaging was further illustrated by the ﬁnding that the median CADD
score for the 30 singletons detected in cases (28.3; IQR 17.6–32.8) was
signiﬁcantly higher than the median CADD score for the 40 singletons
in controls (14.9; IQR 8.1–23.1; P= 5.2 × 10− 5). The median CADD
score of only slightly more common variants did not signiﬁcantly
differ between cases and controls (P= 0.23) (Supplementary
Figure S2).
The median age at onset for carriers of strongly damaging SORL1
singletons (CADD 430, n= 14) was 58.9 years, compared with 65.1
years for cases without these singletons (P= 0.08, one-tailed Mann–
Whitney U-test). The ﬁve cases with carriers of stopcodon/frameshift
mutations had a median age at onset of 57.7 (Supplementary
Results).
Next, we analyzed whether there was a differential burden of
damaging singleton variants in individual SORL1 protein domains
(Table 1C; for affected amino-acid positions in protein see
Supplementary Figure S3). All six subjects who carried a moderately
damaging singleton (CADD 20–30) in the VPS10 domain developed
AD, which was associated with almost 20-fold increased AD risk
(OR= 19.3; 95% CI 3.6–105.2; P= 6.1 × 10− 4), and three out of four
subjects with a strongly damaging variant in the VPS10 domain
(CADD430) developed AD (OR= 6.6; 95% CI 0.82–53.1;
P= 7.6× 10− 2). In contrast, only 1 out of 12 subjects who carried
such a moderately damaging variant in one of the other domains
developed AD.
Replication in published data
We replicated our ﬁndings in 103 SORL1 variants reported in an
independent published data set.6 In this data set, singleton variants
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with CADD430 associated with a 14-fold increased AD risk (OR=
14.1; 95% CI 3.3–60.8; P= 3.5 × 10− 6) and all eight stop-gain/frame-
shift variants were singletons observed exclusively in cases
(P= 5.6 × 10− 4) (Supplementary Table S8). Singleton missense var-
iants with CADD430 associated with an eight-fold increased AD
risk (OR= 7.8; 95% CI 1.7–35.5; P= 2.4× 10− 3). We were not able to
replicate our ﬁndings in the VPS10 domain: moderately
damaging variants in the VPS10 domain were carried only by ﬁve
young control subjects (aged 55, 60 and 62 years and two with
unknown ages).
Table 1 Discovery analysis: 115 SORL1 variants in 640 cases and 1268 controls
CADD score
N-variants in
burden test
Cases
With at least
one variant
Total 640
Controls
With at least one
variant
Total 1268 OR (95% CI)
P-value a
(unadjusted)
A. Variant stratiﬁcation according to sample MAF o0.01 and SIFT/Polyphen and CADD
MAF o0.01
All variants 100 83 140 1.2 (0.9–1.6) 0.23
SIFT/Polyphen damaging 36 40 44 1.9 (1.2–2.9) 7.2×10−3
CADD 0–20 55 42 94 0.9 (0.6–1.3) 0.59
CADD 20–30 26 28 43 1.3 (0.78–2.1) 0.34
CADD 430 19 15 8 4.0 (1.7–9.0) 9.9×10−4
B. Variant stratiﬁcation according to sample MAF and CADD
MAF 40.01 (variants detected in 438 subjects in this sample)
0–20 13 640 1268 1.0 (1.0–1.1) 0.54
20–30 1 48 103 1.0 (0.7–1.3) 0.83
430 1 17 44 0.8 (0.5–1.3) 0.29
0.001oMAF o0.01 (variants detected in 3–38 subjects in this sample
0–20 7 27 47 1.2 (0.7–1.9) 0.54
20–30 3 18 24 1.5 (0.8–2.9) 0.21
430 1 1 3 0.7 (0.1–5.5) 0.73
0.0005oMAF o0.001 (variants detected in 2–3 subjects in this sample)
0–20 12 6 21 0.7 (0.3–1.4) 0.33
20–30 5 3 9 0.7 (0.2–2.4) 0.57
430 2 1 3 0.7 (0.1–5.2) 0.70
MAF o0.0005 (singletons in this sample)
0–20 36 9 26* 0.7 (0.4–1.4) 0.31
20–30 18 7 11 1.3 (0.5–3.3) 0.65
430 16 14 2 11.3 (4.0–32.1) 4.9×10−6
430 missense 11 9 2 8.7 (2.5–30.4) 7.2×10−4
430 stop/frameshift 5 5 0 19.8 (3.1–126.8) b 1.7×10−3
C. Variant stratiﬁcation of singleton variants according to
protein domainc and CADD
VPS10
0–20 5 1 4 0.6 (0.1–3.6) 0.54
20–30 6 6 0 19.3 (3.6–105.2) b 6.1×10−4
430 4 3 1 6.6 (0.8–53.1) 7.6×10−2
LDL A and B
0–20 10 3 7 0.9 (0.2–3.2) 0.81
20–30 4 0 4 0.22 (0.0–1.7) b 0.14
430 8 7 1 10.8 (2.5–46.7) 1.5×10−3
Fibronectin
0–20 3 0 3 0.2 (0.0–2.5) b 0.23
20–30 5 0 5 0.2 (0.0–1.4) b 0.11
430 4 4 0 20.5 (2.6–164.5) b 4.5×10−3
Variants were categorized according to the associated minor allele frequency in the sample and CADD score. For each category, multiple variants per individual were collapsed into one variant such
that an odds ratio and an associated P-value could be calculated using the score-based SeqMeta burden test, while using gender as a covariate. LDL-Receptor, low-density lipoprotein receptor A
and BOR; odds ratio; VPS10, Vacuolar Protein Sorting domain 10. No subject carried more than one singleton, with the exception of one control subject who carried two intronic singletons with
CADD 0–20 (*).
aAssociations that are signiﬁcant after multiple testing correction are shown in bold (Po7.1×10−4).
bResults for the odds ratios can be considered a one-step approximation to the maximum likelihood result, such that ORs of inﬁnite have lower values when controls contribute no variants to the
association.
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Combined analysis
We substantiated the characterization of SORL1 variant pathogenicity
in the 181 unique SORL1 variants in the 1895 cases and 3206 controls
of the combined the discovery and replication samples (Table 2); all
variants are listed in Supplementary Table S5.
SORL1 variants that were (i) novel or listed only once in the
ExAC database (MAF o1 × 10 − 5) and (ii) high predicted variant
damagingness (CADD430) had the largest effect on AD risk
(OR= 12.0; 95% CI 4.2–34.3; P= 5 × 10 − 9) (Table 2 and
Figure 2). Slightly more common variants observed 2–12 × in the
ExAC database (ExAC-MAF between 1 × 10 − 5 and 1 × 10 − 4) with
CADD430 associated with an 8.5-fold increased AD risk (95% CI
1.9–38.8; P= 1.4 × 10 − 3); more common variants with ExAC-
MAF41 × 10 − 4 and CADD430 do not associate with a signiﬁ-
cantly increased AD risk (Table 2 and Figure 2). Together, the
maximum statistical evidence for an effect on AD risk is obtained
for SORL1 variants with CADD430 and ExAC-MAFo1 × 10 − 4
(OR= 10.9; 95% CI 4.6–25.7; P= 1.8 × 10 − 11) (Table 3). SORL1
variants with these characteristics occur in 38 from 1895 cases (2%)
and in 6 from 3206 controls (0.19%).
Extremely rare variants (ExAC-MAF o1× 10− 5) that are moder-
ately damaging (CADD 20–30) and mildly damaging variants (CADD
10–20) are both suggestively associated with a two-fold increased AD
risk (OR= 2.0; 95% CI 0.9–4.5; P= 6.6 × 10− 2) and (OR= 2.18, 95%
CI 0.8–5.9; P= 9× 10− 2), respectively, whereas variants with CADD
0–10 were not associated with any risk increase (OR= 0.4; 95% CI
0.1–2.0; P= 0.93) (Table 2 and Figure 2). In this combined analysis,
we found no evidence that moderately damaging variants in the VPS10
domain are associated with AD (OR= 0.91; 95% CI 0.36–2.29;
P= 0.66).
Table 2 Combined analysis: 181 unique SORL1 variants in 1895 cases and 3206 controls
CADD score
N-variants in
burden test a
Cases
With at least
one variant
Total 1895
Controls
With at least
one variant
Total 3206 OR (95% CI)
P-valueb
(unadjusted))
ExAC-MAF 40.01 (each variant detected in 41200 subjects in the ExAC database)
0–10 8c 1,895 3,206 1.0 1.0
10–20 4c 1,895 3,206 1.0 1.0
20–30 1 203 300 1.2 (1.0–1.4) 7.3×10−2
430 1 67 162 0.7 (0.5–0.9) 1.0
0.001o ExAC-MAFo0.01 (each variant detected in 121–1200
subjects in ExAC database)
0–10 5c 93 158 1.0 (0.8–1.3) 0.52
10–20 4c 68 151 0.8 (0.6–1.0) 0.98
20–30 3 37 40 1.6 (1.0–2.5) 3.2×10−2
430 1 4 7 1.0 (0.3–3.3) 0.63
0.0001o ExAC-MAFo0.001 (each variant detected in 13–120
subjects in ExAC database)
0–10 5 10 12 1.4 (0.6–3.3) 0.27
10–20 5 9 11 1.4 (0.6–3.4) 0.30
20–30 11 15 21 1.2 (0.6–2.4) 0.34
430 4 5 4 2.1 (0.6–7.9) 0.21
0.00001oExAC-MAF o0.0001 (each variant detected in 2–12
subjects in ExAC database)
0–10 5 7 10 1.2 (0.5–3.1) 0.45
10–20 20 9 21 0.7 (0.3–1.6) 0.84
20–30 22 9 23 0.7 (0.3–1.4) 0.90
430 9 10 2 8.5 (1.9–38.8) 1.4×10−3
ExAC-MAFo0.00001 (unknown or singletons in ExAC database)
0–10 7 2 8 0.4 (0.1–2.0) 0.93
10–20 15 9 7 2.2 (0.8–5.9) 9.4×10−2
20–30 22 13 11 2.0 (0.9–4.5) 6.6×10−2
430 29 28 4 12.0 (4.2–34.3) 5.0×10−9
Variants were categorized according to the associated minor allele frequency reported in the ExAC database (ExAC-MAF) and CADD score.
aIn the replication sample, we were not able to account for the overlap when one subject carried multiple variants with the same MAF.
bAssociations that are signiﬁcant after multiple testing correction are shown in bold (Po7.1×10−4).
cFor common variants derived form the replication sample, the variant MAF reported in cases and controls was used to estimate the number of case-carriers and control-carriers.
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Proposed classiﬁcation of SORL1 variants
SORL1 variants with CADD430 and ExAC-MAFo1× 10–4 are
associated with a strong increased AD risk (OR= 10.9; 95% CI 4.6–
25.7; P= 1.8 × 10− 11) (Table 3), but the subset of protein-truncating
SORL1 variants (n= 13) occurred exclusively in AD cases, and they
were novel to ExAC (OR= inf; 95% CI 5.2–inf; P= 2.5 × 10− 6). This
suggests that protein-truncating SORL1 variants may be pathogenic
(Table 3, classiﬁcation: pathogenic). The subset of non-truncating
missense mutations with CADD430 and ExAC-MAFo1× 10− 4
accounted for a 47-fold increased AD risk (OR= 7.1, 95% CI 2.9–
17.4, 8.6 × 10− 7), suggesting that variants with these characteristics are
strong risk factors for AD (Table 3, classiﬁcation: likely pathogenic).
Variants predicted to be mildly-moderately damaging (CADD 10–30)
with ExAC-MAFo1× 10− 5 were associated with 42-fold increased
AD risk (OR= 2.4; 95% CI 1.2–4.6; P= 7.7× 10− 3), suggesting that
variants with these characteristics are risk factors for AD and some
might be pathogenic (Table 3, classiﬁcation: possibly pathogenic).
SORL1 variants with ExAC-MAFo1× 10− 4, including those classiﬁed
pathogenic or likely pathogenic, did not concentrate in speciﬁc SORL1
protein domains (Figure 3).
When we focus on the more common SORL1 variants with
CADD430, with ExAC-MAF410− 4, we found that despite their
high CADD values, they were not associated with increased AD risk
(OR= 0.73; 95% CI 0.6–1.0; P= 0.99) (Table 3, classiﬁcation: most
Figure 2 Only the rarest variants with the highest CADD scores are associated with increased AD risk. The 181 SORL1 variants detected in 5101 AD cases
and controls from the combined analysis were ﬁrst separated by their ExAC-MAF, and then by their CADD values (see also Table 2).
Table 3 Clinical selection criteria of variants
Variant selection criteria CADD ExAC-MAF v.0.3.1
N-variants in
burden test a
Cases
With at least
one variant
Total 1895
Controls
With at least one
variant
Total 3206 OR (95% CI)
P-value a
(unadjusted)
A. Effect on AD risk
Maximum effect size 430 o1×10−5 29 28 4 12.0 (4.2–34.3) 5.0×10−9
Maximum evidence for effect 430 o1×10−4 38 38 6 10.9 (4.6–25.9) 1.8×10−11
B. Suggested variant subtypes
Pathogenic 430 (truncating) o1×10−5b 13 13 0 inf (5.2– inf) 2.5×10−6
Likely pathogenic 430 (missense) o1×10−4 25 25 6 7.1 (2.9–17.4) 8.6×10−7
Uncertain signiﬁcance
Possibly pathogenic 10–30 o1×10−5 33 21 15 2.4 (1.2–4.6) 7.7×10−3
Most likely not pathogenic 430 41×10−4 6 76 173 0.73 (0.6–1.0) 0.99
Likely benign 10–30 41×10−5 70 1,895 3,206 1.0 1.0
Benign 0–10 0–1 30 1,895 3,206 1.0 1.0
aAssociations that are signiﬁcant after multiple testing correction are shown in bold (Po7.1×10−4).
bStop/frameshift mutations were all unknown to the ExAC database v.0.3.1.
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likely not pathogenic). For SORL1 variants observed more often in the
ExAC database than ExAC-MAF410− 5 with CADD values o30, we
found no association with AD risk (Table 3, classiﬁcation: likely
benign). Likewise, variants with CADD 0–10, regardless of their rarity,
were not associated with increase AD risk (Table 3, classiﬁcation:
benign).
Our ﬁndings lead us to propose the following ﬁve SORL1 variant
subtypes:
Pathogenic. Truncating SORL1 variants.
Likely pathogenic. SORL1 variants predicted extremely damaging
(CADD430) and extremely rare (MAF o1× 10− 4 in the publically
available ExAC database v.0.3.131).
Uncertain signiﬁcance. Possibly pathogenic: variants predicted mildly
to moderately damaging (CADD 10–30) which are novel or reported
only once in the ExAC database (ExAC-MAF o1× 10− 5).
Most likely not pathogenic: variants predicted extremely damaging
(CADD430) that are observed more commonly in the ExAC database
(ExAC-MAF ≥ 1× 10− 4).
Likely benign. SORL1 variants predicted mildly- moderately dama-
ging (CADD 10–30) that are reported more than once in the ExAC
database (ExAC-MAF ≥ 1× 10− 5).
Benign. SORL1 variants predicted not damaging (CADD 0–10)
regardless of their rareness.
Application of SORL1 variant pathogenicity screen
We applied our classiﬁcation approach to the 17 SORL1 prioritized
variants detected in a family based analysis.4 These variants were
enriched in members from 87 Caribbean Hispanic families affected
with late onset AD, compared with 498 age-matched controls.
Vardarajan et al. identiﬁed three truncating deletions unknown to
the ExAC database. Our approach to screen for variant pathogenicity
classiﬁed these variants to be ‘pathogenic’ and indeed these variants
were detected exclusively in families affected with AD. Furthermore,
13 variants are classiﬁed ‘likely benign’, they had CADD scores o30
and occur more than once in ExAC; indeed, these variants were
detected both in the affected families and non-affected families. One
variant with CADD score 34 and ExAC-MAF40.01 occurred both in
affected families and in unaffected controls; in accordance, our
approach classiﬁed it to be ‘most likely not pathogenic’.
Likewise, we applied our classiﬁcation strategy to SORL1 variants
reported by Nicolas et al.5 They studied 24 rare variants (sample MAF
o0.01) that were predicted deleterious by SIFT and Polyphen in 484
AD cases, mostly with family history of AD, and 498 controls. Of these
variants, 15 were novel to the ExAC database: 8 truncating variants
and 7 missense variants with CADD 430 that were classiﬁed as
‘pathogenic’ and ‘likely pathogenic’ variants, respectively; indeed, these
were seen exclusively in cases. Another case carried a variant with
CADD score 35 with ExAC-MAF 6×10− 5 classiﬁed to be ‘likely
pathogenic’; indeed, this variant was also detected in two cases in the
Verheijen sample. Furthermore, Nicolas et al. detected a SORL1
variant unknown to ExAC with CADD score 32, which was located
within the VPS10 domain. This ‘likely pathogenic’ variant was found
to disturb the binding of Aβ for lysosomal degradation12 and Pottier
et al.3 found that this variant segregated with disease. Nicolas et al. also
detected a variant with ExAC-MAF 0.003 and CADD score 25.5,
which was classiﬁed to be ‘likely benign’: indeed, it occurred equally in
cases and controls. Finally, Nicolas et al. identiﬁed seven ‘possibly
pathogenic’ variants that were novel to ExAC with CADD scores
ranging between 26.7 and 29.4, all occurred in AD cases. The evidence
for the association with AD of variants with these characteristics is
Figure 3 Protein position of SORL1 variants with MAF o1×10−4 in ExAC database. One hundred and twenty-one coding variants with ExAC-MAF
o1×10−4 were detected the combined analysis of 5101 subjects (1895 cases and 3206 controls). Each symbol represents one case carrier (red) or control
(green) carrier. Protein domains are depicted on the CADD=20 level, variants with CADD scores between 20 and 30 are considered ‘moderately damaging’
and variants with CADD scores 430 were considered ‘strongly damaging’. Markers outlined in black represent variants that were detected in multiple cases
or in multiple controls.
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relatively low, suggesting that further research into the pathogenicity of
these variants is necessary.
DISCUSSION
Protein truncating and rare pathogenic missense variants in the
SORL1 gene associate with AD
It is clear that nonfunctional SORL1 associates with AD, but a
comprehensive set of characteristics that deﬁnes the associated genetic
variants and their impact has been lacking. Therefore, the ‘need for
pathogenicity assays’ has been raised to aid with the clinical inter-
pretation of SORL1 variants.6 Here, we analyzed 181 unique SORL1
variants detected in a large sample of 1895 cases and 3206 controls and
we propose that SORL1 variant-pathogenicity can be classiﬁed
according to the combination of two independent variant character-
istics: the predicted level of variant damagingness and the level of
variant-rareness.
Our ﬁndings indicate that stop-gain and frameshift mutations
occurred exclusively in cases, suggesting that variants leading to
premature disruption of SORL1 transcription are highly penetrant.
This supports previous ﬁndings that loss of one copy of SORL1 (i.e.,
haploinsufﬁciency) is causal to AD.6 Thus far, such high impact on
AD is observed only for variants in PSEN1/2 and APP, which are
associated with familial AD.25 Furthermore, our ﬁndings indicate that
variants novel to the ExAC database with a CADD score 430 are
associated with a signiﬁcant 12-fold increased AD risk, which is
comparable to the effect of APOE-ε4 homozygosity.25 In line with the
increased risk, we found suggestive evidence that pathogenic SORL1
variants lead to an earlier age at onset.
Although variants are individually rare, 2% of the AD cases (and
o0.2% of the controls) in our analysis carried a SORL1 variant with
these characteristics. By comparison, variants in the classical AD genes
PSEN1, PSEN2 and APP collectively explain o1% of AD cases.25 We
propose therefore that in clinical practice, rare pathogenic SORL1
mutations should be considered next to PSEN1, PSEN2 and APP.
Moderately damaging variants in the VPS10 domain might be
associated with AD
Pathogenic variants occurred throughout the SORL1 gene without
preference to a speciﬁc functional domain. In our discovery analysis,
moderately damaging variants in the VPS10 domain were detected
only in four cases but not in older controls. In contrast, moderately
damaging variants in the LDL-receptor A and ﬁbronectin domains
occurred only in control subjects. However, we could not conﬁrm
these ﬁndings in the replication or combined sample, possibly due to
the many young control subjects in the replication sample who might
still develop disease at a later age. In the future, larger samples will
have to clarify whether or not moderately damaging variants in the
Aβ-binding VPS10 domain might dangerously affect SORL1 function.
Our results indicate that some SORL1 variants with lower CADD
scores may hold some pathogenicity when they are extremely rare, but
the effect size is only two-fold and the evidence for this is not as
strong. On the other hand, we found no evidence for pathogenicity for
common variants, even variants with CADD scores 430. Risk
increases were independent of gender and we detected no evidence
for synergy between disrupted SORL1 function and carrying the
APOE-ε4 genotype.
Five SORL1 variant subtypes
For the clinical interpretation of SORL1 variant pathogenicity based on
ExAC-MAF and CADD scores, we propose ﬁve SORL1 variant
subtypes according to the ﬁve-class system of variant pathogenicity
supported by the ACMG32 and ACGS.33 When we applied our strategy
to SORL1 variants reported by the independent studies of Vardarajan
et al.4 and Nicholas et al.,5 variants were classiﬁed according to their
occurrence in cases and controls. Even though the classiﬁcation
strategy presented here is based on two large samples, additional
research is necessary to determine the exact risk of individual variants.
We caution that genetic context might inﬂuence variant pathogenicity:
for example, one possibly pathogenic SORL1 variant (CADD score
23.6, ExAC-MAFo1× 10− 5) was found to segregate with disease and
increase AD risk in a family with several generations of APOE-ε4
homozygosity.39 It is likely that classiﬁcation will be reﬁned as larger
samples with sequencing data become available. Lastly, this classiﬁca-
tion is based on evidence from populations with European ancestry
and should be replicated in populations with other ethnic
backgrounds.
Pathogenic SORL1 variants are rare
We ﬁnd that truncating SORL1 variants are pathogenic: all 24
truncating variants collectively reported across the previous studies
by Verheijen et al., Nicolas et al., Vardarajan et al. and this present
study occurred exclusively in AD cases and were unknown to the
ExAC database. Likewise, across these studies, 470% of all likely
pathogenic variants (missense variants with CADD score 430) were
unknown to ExAC. This suggests that the increased pathogenicity of
extremely rare variants may explain part of the ‘missing heritability’
that remained undetected in genetic association studies such as
GWAS, which test the association of common variants with disease.
In concordance with this, evidence is mounting that especially
extremely rare mutations are the major contributors to the develop-
ment of disease. In a sequencing analysis of 202 drug-targeted genes in
14 002 persons, 74% of the detected mutations occurred only in one
or two subjects, indicating that mutations that associated with disease
are abundant, but mostly very rare.40 Furthermore, Fu et al.41 found
that more than half of all SNPs detected in exomes from 6515
individuals were, in fact, singletons. They found that 86% of detected
damaging variants arose very recently in the population, which partly
explains the restricted propagation of the variant in the population,
that is, the variant rarity relative to common (old) variants.41
The rarity of the variants also suggests that natural selection
pressure eliminates pathogenic SORL1 variants from the population.
As AD onset occurs well after the reproductive phase, we might expect
that variants associated with AD would not be under inﬂuence of
selection pressure. Therefore, it is surprising that pathogenic SORL1
variants are not propagated in the population. The rarity of harmful
SORL1 variants suggests that SORL1 function may not be restricted to
the maintenance of cells in the brain and that disturbed SORL1
function might affect reproductive success and/or individual health far
before the age of AD onset.
CONCLUSION
With the increasing availability of whole-exome sequencing in clinical
practice, it is possible to detect highly personal exonic variants in
SORL1. We characterized SORL1 variants based on variant frequency
and damagingness and we suggest ﬁve variant subtypes ranging from
pathogenic to benign. Our ﬁndings suggest that in the clinic,
pathogenic SORL1 variants should be considered in personalized AD
risk assessments alongside APOE, PSEN1, PSEN2, and APP.
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